MedTrace Logo

Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL

NCT05883449 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2025-08-20

Study results available
· View outcomes & findings →

Summary

AFM13-203 is a phase 2, open-label, multi-center, multi-cohort study with a safety run-in followed by expansion cohorts. The study is evaluating the safety and efficacy of AFM13 in combination with AB-101 in subjects with R/R classical HL and CD30-positive PTCL.

Conditions

  • Relapsed or Refractory Hodgkin Lymphoma
  • Peripheral T Cell Lymphoma

Interventions

DRUG

AFM13

anti-human CD30 × anti-human CD16A recombinant antibody therapy, intravenous infusion

DRUG

AB-101

NK cell therapy, intravenous infusion

DRUG

Cyclophosphamide

Lymphodepleting chemotherapy, intravenous infusion

DRUG

Fludarabine

Lymphodepleting chemotherapy, intravenous infusion

DRUG

Interleukin-2

Immune cytokine, subcutaneously

Sponsors & Collaborators

  • Artiva Biotherapeutics, Inc.

    collaborator INDUSTRY

  • Affimed GmbH

    lead INDUSTRY

Principal Investigators

  • Wunderle Lydia, MD · Affimed Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-10
Primary Completion
2024-11-07
Completion
2025-06-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05883449 on ClinicalTrials.gov